This project is developing a novel disease-modifying compound for Alzheimer's disease (AD).
The primary objective of this study is to evaluate for an effect of food consumption on the pharmacokinetics profile of BMS984923. Safety and tolerability is also assessed.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Enrollment
12
Oral capsule
Spaulding Clinical Research
West Bend, Wisconsin, United States
Maximum Plasma Concentration (Cmax)
Maximum plasma concentration as determined by pharmacokinetic modeling
Time frame: Up to 10 days after last dose
Time of Cmax (Tmax)
Time of Cmax as determined by pharmacokinetic modeling
Time frame: Up to 10 days after last dose
Area Under the Curve from 0 to 24h (AUC 24h)
Plasma drug exposure as determined by pharmacokinetic modeling
Time frame: Up to 10 days after last dose
Incidence of Treatment Emergent Adverse Events (TEAE)
Safety
Time frame: 14 days
Safety Laboratory abnormalities
Safety
Time frame: 14 days
Electrocardiogram - QT Interval
Safety
Time frame: 14 days
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.